![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Projections Using Decision-Analytic Modeling of Long-Term Clinical Value of Telaprevir for the Treatment of HCV Patients Who Had Failed Prior Peginterferon/Ribavirin Treatment
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
Baris Deniz, MSc1; Anita J Brogan, PhD2; Jeffrey D Miller, MS3; Sandra E Talbird, MSPH2; James R Thompson, MS2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2RTI Health Solutions, Research Triangle Park, NC, United States; 3RTI Health Solutions, Waltham, MA, United States
![AASLD1.gif](../images/111711/111711-7/AASLD1.gif)
![AASLD2.gif](../images/111711/111711-7/AASLD2.gif)
![AASLD3.gif](../images/111711/111711-7/AASLD3.gif)
![AASLD4.gif](../images/111711/111711-7/AASLD4.gif)
![AASLD5.gif](../images/111711/111711-7/AASLD5.gif)
![AASLD6.gif](../images/111711/111711-7/AASLD6.gif)
![AASLD7.gif](../images/111711/111711-7/AASLD7.gif)
![AASLD8.gif](../images/111711/111711-7/AASLD8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|